Showing 1-10 of about 148 articles.
Friedreich's Ataxia Research Alliance
DOWNINGTOWN, Pa., Dec. 05, 2019 (GLOBE NEWSWIRE) -- The Board of Directors at The Friedreich’s Ataxia Research Alliance (FARA) today announced the promotion of Jennifer Farmer, MS to the role of...
Centogene AG
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Dec. 05, 2019 (GLOBE NEWSWIRE) -- CENTOGENE N.V. (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world...
The Children's Inn at NIH
Bethesda, Maryland, Nov. 26, 2019 (GLOBE NEWSWIRE) -- One Texas family has lots to be thankful for this Thanksgiving. Their daughter, now 13, is doing well after undergoing a bone marrow...
Syneos Health, Inc.
MORRISVILLE, N.C. and NEW YORK , Nov. 21, 2019 (GLOBE NEWSWIRE) -- Syneos Health® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, today released “Real World Value:...
ProQR Therapeutics N.V.
LEIDEN, Netherlands and CAMBRIDGE, Mass., Nov. 21, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of...
Centogene AG
CAMBRIDGE, Ma. and ROSTOCK, Germany, Nov. 18, 2019 (GLOBE NEWSWIRE) -- Centogene N.V. (NASDAQ: CNTG), a commercial-stage company focused on rare diseases that transforms real-world clinical and...
Retrophin, Inc.
SAN DIEGO, Nov. 14, 2019 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced that Eric Dube, Ph.D., chief executive officer, will present at the Jefferies 2019 London Healthcare...
Rubius Therapeutics
CAMBRIDGE, Mass., Nov. 14, 2019 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an...
Centogene AG
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Nov. 13, 2019 (GLOBE NEWSWIRE) -- CENTOGENE (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world clinical...
Retrophin, Inc.
Enrollment on-track in pivotal Phase 3 clinical trials to support registration of sparsentan for patients with FSGS and IgAN Third quarter revenues rose nine percent to $44 million ...
Showing 1-10 of about 148 articles.
